North Dallas Bank & Trust Co. Acquires New Shares in Eli Lilly and Company $LLY

North Dallas Bank & Trust Co. acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the 4th quarter, Holdings Channel reports. The firm acquired 1,618 shares of the company’s stock, valued at approximately $1,739,000. Eli Lilly and Company accounts for approximately 1.1% of North Dallas Bank & Trust Co.’s holdings, making the stock its 27th largest holding.

Several other hedge funds have also recently bought and sold shares of LLY. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares in the last quarter. 10Elms LLP increased its position in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its position in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares in the last quarter. Finally, Miller Global Investments LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LLY. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and dropped their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Wolfe Research reissued an “outperform” rating and set a $1,350.00 price target on shares of Eli Lilly and Company in a research report on Thursday, May 21st. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Guggenheim reissued a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,227.74.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,143.29 on Wednesday. The company has a market cap of $1.08 trillion, a P/E ratio of 40.61, a P/E/G ratio of 1.26 and a beta of 0.53. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,182.73. The business has a fifty day simple moving average of $984.90 and a 200-day simple moving average of $1,014.46.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The business’s revenue for the quarter was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts forecast that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Positive Phase 3 data for retatrutide showed strong weight-loss results and benefits for obesity-related conditions, boosting expectations that Lilly can extend its lead in the GLP-1/obesity market. Reuters: Lilly shares jump as analysts see retatrutide data extending obesity market edge
• Positive Sentiment: New data on Lilly’s oral GLP-1 Foundayo (orforglipron) showed superior A1C control and weight loss versus oral semaglutide in type 2 diabetes trials, and additional analyses highlighted weight-loss benefits for women across menopausal stages. PR Newswire: Lilly’s oral GLP-1 Foundayo delivered superior A1C control and weight loss
• Positive Sentiment: The FDA approved an every-eight-weeks maintenance dosing regimen for EBGLYSS in moderate-to-severe atopic dermatitis, which could improve convenience and support adoption in Lilly’s dermatology franchise. PR Newswire: FDA approves Lilly’s EBGLYSS every eight weeks
• Positive Sentiment: Lilly also expanded its Alzheimer’s pipeline through a collaboration with AlzeCure Pharma for global rights to ACD680, adding optionality beyond obesity and diabetes. Yahoo Finance: Eli Lilly Expands Alzheimer’s Pipeline With AlzeCure Deal
• Neutral Sentiment: Broader sector rotation into healthcare and defensive stocks is also helping sentiment around Lilly as investors pull back from tech and AI names. Investopedia: As Tech Stocks Slide, The Healthcare Sector Shines

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.